ライフサイエンスコーパス: leukotriene B

1 application to a concise total synthesis of leukotriene B(3).

2 ically active dose of fMLP (5 x 10(-9) M) or leukotriene B(4) (1 x 10(-7) M) in the presence of a phy

3 d miR-219-5p expression along with increased leukotriene B(4) (5-fold) and decreased (~3-fold) specia

4 (FR), platelet-activating factor (PAFR), and leukotriene B(4) (BLTR) were transfected into RBL-2H3 ce

5 whether 15-epi-LXA(4) (anti-inflammatory) or leukotriene B(4) (inflammatory mediator) is produced.

6 ic steps: increased arachidonic acid-derived leukotriene B(4) (LTB(4)) and decreased 5S-hydroxyeicosa

7 k saliva, has dual functions of sequestering leukotriene B(4) (LTB(4)) and inhibiting complement comp

8 te requirement for the lipid chemoattractant leukotriene B(4) (LTB(4)) and its receptor BLT1 for neut

9 Leukotriene B(4) (LTB(4)) and leukotriene C(4) (LTC(4))

10 ecific binding to human PMN was displaced by leukotriene B(4) (LTB(4)) and LTB(4) receptor 1 (BLT1) a

11 V phospholipase A(2) (hVPLA(2)) could elicit leukotriene B(4) (LTB(4)) biosynthesis in human neutroph

12 inflammatory cell death termed "pyroptosis." Leukotriene B(4) (LTB(4)) is a lipid mediator produced q

13 Leukotriene B(4) (LTB(4)) is a potent chemoattractant ac

14 Leukotriene B(4) (LTB(4)) is a potent chemoattractant fo

15 Leukotriene B(4) (LTB(4)) is a potent lipid mediator of

16 Leukotriene B(4) (LTB(4)) is a potent proinflammatory li

17 Leukotriene B(4) (LTB(4)) is a potent, proinflammatory m

18 Leukotriene B(4) (LTB(4)) is a pro-inflammatory mediator

19 Leukotriene B(4) (LTB(4)) is a product of eicosanoid met

20 blished in dogs using ex vivo measurement of leukotriene B(4) (LTB(4)) levels in blood with good corr

21 Leukotriene B(4) (LTB(4)) mediates a variety of inflamma

22 2/TMPRSS2), and for the main molecule of the leukotriene B(4) (LTB(4)) pathway (ALOX5).

23 were complemented by biochemical analyses of leukotriene B(4) (LTB(4)) production and activation of t

24 Leukotriene B(4) (LTB(4)) receptor (BLT)1 is expressed o

25 a lead optimization effort starting with the leukotriene B(4) (LTB(4)) receptor antagonist (2), membe

26 ple chemoattractant receptors, including the leukotriene B(4) (LTB(4)) receptor BLT1 and the chemokin

27 e by releasing the secondary chemoattractant leukotriene B(4) (LTB(4)) refs.

28 PMN leukotriene B(4) (LTB(4)) synthesis was also augmented a

29 Current immunoassays for the measurement of leukotriene B(4) (LTB(4)) typically utilize an enzyme-li

30 ation of leukotriene synthesis, and produced leukotriene B(4) (LTB(4)) when stimulated with the calci

31 ls, vitamin E forms differentially inhibited leukotriene B(4) (LTB(4)) with an IC(50) of 5-20 muM for

32 catalyzes the final step in the synthesis of leukotriene B(4) (LTB(4)), a potent chemoattractant and

33 tiple Yop effectors can inhibit synthesis of leukotriene B(4) (LTB(4)), a potent lipid mediator relea

34 Current models propose that leukotriene B(4) (LTB(4)), a secondary chemoattractant s

35 (cys-LTs), prostaglandin E(2) (PGE(2)), and leukotriene B(4) (LTB(4)), and also 8-isoprostane as a m

36 factor (PAF), interleukin-8 (IL-8), C5a, and leukotriene B(4) (LTB(4)), and it was normal.

37 hil influx, along with cytokines/chemokines, leukotriene B(4) (LTB(4)), and vascular cell adhesion mo

38 Leukotriene B(4) (LTB(4)), interacting with its high-aff

39 Receptors for leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)),

40 r, the role of CXCL1 in mediating neutrophil leukotriene B(4) (LTB(4)), reactive oxygen species (ROS)

41 hibited the formation of the chemoattractant leukotriene B(4) (LTB(4)), specifically in human neutrop

42 LTA(4)H knockdown limited the formation of leukotriene B(4) (LTB(4)), the enzymatic product of LTA(

43 We have recently shown that the leukotriene B(4) (LTB(4))-BLT1 pathway is important in e

44 D1 (RvD1) and pro-inflammatory factors, like leukotriene B(4) (LTB(4)).

45 l mucosal injury and decreased generation of leukotriene B(4) (LTB(4)).

46 s expression of the proinflammatory mediator leukotriene B(4) (LTB(4)).

47 zyme in the biosynthesis of pro-inflammatory leukotriene B(4) (LTB(4)).

48 ctive oxygen species, and the lipid mediator leukotriene B(4) (LTB(4)).

49 he inflammatory mediator and chemoattractant leukotriene B(4) (LTB(4)).

50 yme that generates the inflammatory mediator leukotriene B(4) (LTB(4)).

51 Similar results were obtained with leukotriene B(4) (LTB(4)).

52 acrophage migration inhibitory factor (MIF), leukotriene B(4) (LTB4), and high mobility group box 1 p

53 activity (p < 0.002) and the chemoattractant leukotriene B(4) (p < 0.02), which fell from a median ba

54 5-oxoprostaglandin 13-reductase, also termed leukotriene B(4) 12-hydroxydehydrogenase (PGR/LTB(4)DH),

55 It is also known for its leukotriene B(4) 12-hydroxydehydrogenase activity.

56 decreased levels of mRNA encoding GST Mu 1, leukotriene B(4) 12-hydroxydehydrogenase, and LMP7.

57 , GST Mu 5, a hypothetical GST Mu, GST Pi B, leukotriene B(4) 12-hydroxydehydrogenase, and proteasome

58 evels of SPMs and proinflammatory mediators (leukotriene B(4) [LTB(4) ] and prostaglandins) were meas

59 ammatory reactions investigated (elicited by leukotriene B(4) [LTB(4)], CXCL1, tumor necrosis factor

60 The 5-lipoxygenase (5LO) produces leukotriene B(4) and 15-epilipoxin-A(4) (15-epi-LXA(4)).

61 zymosan-stimulated PMN showed predominantly leukotriene B(4) and 20-OH-leukotriene B(4), as well as

62 tic increase (>50-fold) in the production of leukotriene B(4) and 5-hydroxyeicosatetraenoic acid, sig

63 The major metabolites of AA made by PMN, leukotriene B(4) and 5-hydroxyicosatetraenoate, did not

64 which also catalyzes omega-hydroxylation of leukotriene B(4) and arachidonic acid.

65 bited calcium ionophore-induced leukotriene (leukotriene B(4) and leukotriene C(4)) production, indic

66 l4 deficiency had a significant reduction in leukotriene B(4) and PGE(2) levels in peritoneal exudate

67 ro with the TLR4 agonist, LPS, the levels of leukotriene B(4) and PGE(2) were also significantly decr

68 ularly N-formylated tripeptides and possibly leukotriene B(4) and platelet activating factor.

69 d lipid inflammatory mediator dihydroxylated Leukotriene B(4) and proresolving mediators such as tri-

70 x 10(5) cells; P < .01) and lower amounts of leukotriene B(4) and prostaglandin than M1.

71 rgoing apoptosis produced similar amounts of leukotriene B(4) and significantly greater amounts of PG

72 but not Epac-1, suppressed AM production of leukotriene B(4) and TNF-alpha, whereas stimulation of e

73 6-fold higher than the K(m) of CYP4F3A using leukotriene B(4) as a substrate.

74 Z,10E,14Z-eicosatetraenoic acid, and 6-trans-leukotriene B(4) Bioinformatics and experimental approac

75 nd protein excretion) and ex vivo glomerular leukotriene B(4) biosynthesis at 3 hr, and up to 4 days,

76 0 4F3 (CYP4F3) catalyzes the inactivation of leukotriene B(4) by omega-oxidation in human neutrophils

77 date cells showed no detectable responses to leukotriene B(4) confirming the deletion of the BLT1/BLT

78 ine phosphorylation of Vav1, whereas IL-8 or leukotriene B(4) did not, correlating with the requireme

79 PGE(2) and leukotriene B(4) each enhanced development of periodonti

80 The synthesis of leukotriene B(4) from arachidonic acid requires the sequ

81 ith significant reductions in the release of leukotriene B(4) from stimulated neutrophils and of inte

82 y for hypoxia-induced lipid peroxidation and leukotriene B(4) generation.

83 and trachea of Dhrs9(-/-) mice toward 1 muM Leukotriene B(4) is 1.7- to 6-fold lower than that of mi

84 , and trachea of Dhrs9(-/-) mice toward 1 uM Leukotriene B(4) is 1.7- to 6-fold lower than that of mi

85 Leukotriene B(4) is a proinflammatory lipid mediator gen

86 tazone plus atorvastatin plus H-89 increased leukotriene B(4) levels.

87 Neutrophil production of IL-1 and leukotriene B(4) likely contributes to inflammation but

88 Leukotriene B(4) mediates diverse inflammatory diseases

89 did not significantly reduce NCA induced by leukotriene B(4) or complement-activated serum.

90 ls with the chemotactic peptide fMLP or with leukotriene B(4) or fibrinogen results in little increas

91 fically prolonged in response to PAF but not leukotriene B(4) or N-formyl-Met-Leu-Phe.

92 olic phospholipase A(2) (cPLA(2)) to produce leukotriene B(4) or with cyclooxygenase-2 (COX2) to prod

93 eutrophil fatty acid composition and ex vivo leukotriene B(4) production from stimulated neutrophils

94 its high-affinity G protein-coupled receptor leukotriene B(4) receptor 1 (BLT1) direct dectin-1-depen

95 is study, we report that the LTB(4) receptor leukotriene B(4) receptor 1 (BLT1) redistributes from no

96 RvE1 through the leukotriene B(4) receptor BLT1 enhanced NADPH oxidase-de

97 ated an important role for the high-affinity leukotriene B(4) receptor BLT1 in arthritis, atheroscler

98 One leukotriene B(4) receptor has been recently identified (

99 onstrated marked expression of 5-LOX and the leukotriene B(4) receptor in human pancreatic cancer tis

100 (+) monocytes in wild-type mice that express leukotriene B(4) receptor, BLT-1, and that this increase

101 BLT2, a low-affinity leukotriene B(4) receptor, was also shown to be a high-a

102 ors with opposing functions, namely ALXR and leukotriene B(4) receptors (BLTs), revealed that the sev

103 of neutrophils, which migrate in response to leukotriene B(4) released by macrophages through 5-lipox

104 Leukotriene B(4) signals primarily through its high-affi

105 crease by approximately 300% in 4 h, whereas leukotriene B(4) stimulated PMN to migrate the full thic

106 iae and reduced calcium-ionophore-stimulated leukotriene B(4) synthesis in vitro.

107 , alveolar macrophage bacterial killing, and leukotriene B(4) synthesis.

108 apacity of stimulated neutrophils to produce leukotriene B(4) was decreased by 31%.

109 Leukotriene B(4) was down-regulated in M2 (668 +/- 81 vs

110 induced in the joints, and the 5-LO product leukotriene B(4) was produced.

111 ammatory derivatives (prostaglandin E(2) and leukotriene B(4)) and an increased anti-inflammatory der

112 nce of ciprofibrate, a synthetic ligand, and leukotriene B(4), a natural ligand.

113 ment in vivo in response to eotaxin, but not leukotriene B(4), a phenomenon that could be prevented b

114 icosatetraenoic acids and, most importantly, leukotriene B(4), an inflammatory mediator involved in l

115 ptide-78, granulocyte chemotactic protein-2, leukotriene B(4), and FMLP.

116 the synovial fluid, TNF-alpha, IL-8, PGE(2), leukotriene B(4), and leukotriene C(4) levels were signi

117 taxis to formylmethionylleucylphenylalanine, leukotriene B(4), and platelet-activating factor was com

118 PG)E(2) and 5-lipoxygenase-derived products, leukotriene B(4), and the biosynthesis interaction produ

119 andin F(2a), prostaglandin D(2) metabolites, leukotriene B(4), and thromboxane levels were lower in s

120 wed predominantly leukotriene B(4) and 20-OH-leukotriene B(4), as well as lipoxin marker 5,15-diHETE.

121 nt by C5a in vivo required amplification via leukotriene B(4), because both C5a-mediated leukocyte re

122 resences of four different chemoattractants (leukotriene B(4), chemokine C-X-C motif ligands 2 and 8,

123 Q0(bolton)-AAT bound IL-8 and leukotriene B(4), comparable to healthy control M-AAT, a

124 hod allows prostaglandins, thromboxane B(2), leukotriene B(4), hydroxyeicosatetraenoic acid isomers,

125 ly minimal production of prostaglandin E(2), leukotriene B(4), or lipoxin A(4) was detected.

126 entrations and was associated with a fall in leukotriene B(4), which is thought to be central to the

127 mponent C5a activates neutrophils to produce leukotriene B(4), which stimulates reactive oxygen speci

128 age activation in vivo and the production of leukotriene B(4), which was required for optimal immune

129 tes (PMN) in vitro chemotaxis in response to leukotriene B(4), with the maximum inhibition ( approxim

130 n of lesional FLAP in myeloid cells promotes leukotriene B(4)-dependent VSMC phenotypic modulation, i

131 y control M-AAT, and significantly decreased leukotriene B(4)-induced neutrophil adhesion (p = 0.04).

132 ally stable LXA(4) analog potently inhibited leukotriene B(4)-induced superoxide anion generation, th

133 RvD1 and RvD2 each reduced MCP-1 and leukotriene B(4)-stimulated monocyte adhesion to adipocy

134 ing in the conversion of arachidonic acid to leukotriene B(4).

135 duce VSMC migration ex vivo was rescued with leukotriene B(4).

136 PtdIns are hydroxyeicosatetraenoic acids or leukotriene B(4).

137 d neutrophil and monocyte trafficking toward leukotriene B(4).

138 ion and PD1/NPD1 levels as well as decreased leukotriene B(4).

139 oxins and hyperinflammation driven by excess leukotriene B(4).

140 e chemoattractants of fMLP > CXCL8 > CXCL2 > leukotriene B(4).

141 MPhi efferocytosis, an action not shared by leukotriene B(4).

142 receptors for the 5-lipoxygenase metabolite leukotriene B(4).

143 with structurally related lipids PGE(2) and leukotriene B(4).

144 whereas it was normal in response to IL-8 or leukotriene B(4).

145 n of proinflammatory lipid mediators such as leukotriene B(4).

146 receptor of the downstream 5-LOX metabolite, leukotriene B(4).

147 eutrophil chemoattractants interleukin-8 and leukotriene B(4).

148 vity and tumor regression were suppressed in leukotriene B(4)R-deficient (BLT-1(-/-)) mice.

149 We measured leukotriene-B(4) (LTB(4)) and LTC(4)/D(4)/E(4), inflamma

150 Conversely, whereas IL-8 and leukotriene-B(4)-mediated transmigration is PECAM-1-inde